Global RNA Targeted Therapeutics Market Size To Exceed USD 37.05 Billion By 2035 | CAGR of 35.23%
Category: HealthcareGlobal RNA Targeted Therapeutics Market Size To Exceed USD 37.05 Billion By 2035
According to a research report published by Spherical Insights & Consulting, The Global RNA Targeted Therapeutics Market Size is Expected to Grow from USD 1.34 Billion in 2024 to USD 37.05 Billion by 2035, at a CAGR of 35.23% during the forecast period 2025-2035.
Get more details on this report -
Browse key industry insights spread across 233 pages with 102 Market data tables and figures & charts from the report on the “Global RNA Targeted Therapeutics Market Size, Share, and COVID-19 Impact Analysis, By Type of Target Molecule (Cap Binding Complex, CDKL5, Dystrophin Protein, G542X, MNK1/MNK2, PAX6 gene, and SMN2), By Type of Approach (Indirect RNA Targeting, mRNA Translation Modulation, and RNA Splicing Modification), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 – 2035.” Get Detailed Report Description Here: https://www.sphericalinsights.com/reports/rna-targeted-therapeutics-market
The RNA targeted therapeutics market refers to the industry focusing on the development and commercialization of drugs that directly interact with RNA molecules to treat or prevent diseases. RNA-targeted therapy is the field of medicine that utilizes RNA molecules as a means for treating diseases by modulating gene expression. An upsurge in the development of RNA aptamer-based products is offering growth opportunities among key market players, thereby escalating the market growth. The growing prevalence of genetic disorders & cancer is driving the demand for RNA-targeted therapeutics by precisely targeting the specific RNA molecules involved in disease pathways. Research & development investment driven by the success of mRNA vaccines and the potential of RNA to address previously undruggable targets in RNA-targeted therapeutics is propelling the market growth. However, the increased development & manufacturing costs, as well as challenges associated with the delivery & risk of off-target effects, are challenging the market growth.
The cap binding complex segment dominated the RNA targeted therapeutics market in 2024 and is projected to grow at a substantial CAGR during the forecast period.
Based on the type of target molecule, the RNA targeted therapeutics market is divided into cap binding complex, CDKL5, dystrophin protein, G542X, MNK1/MNK2, PAX6 gene, and SMN2. Among these, the cap binding complex segment dominated the RNA targeted therapeutics market in 2024 and is projected to grow at a substantial CAGR during the forecast period. The central role of the cap binding complex for initiating mRNA translation, which is vital for various cellular processes, including mRNA stability, translation, and other post-transcriptional events, is propelling the market.
The indirect RNA targeting segment accounted for the largest market share in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period.
Based on the type of approach, the RNA targeted therapeutics market is divided into indirect RNA targeting, mRNA translation modulation, and RNA splicing modification. Among these, the indirect RNA targeting segment accounted for the largest market share in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period. An increased investment in RNA-targeted therapies and advancements in drug discovery technologies, with the rising prevalence of cancer & genetic disorders, are propelling the market growth.
North America is expected to hold the majority share of the global RNA targeted therapeutics market during the forecast period.
Get more details on this report -
North America is expected to hold the majority share of the global RNA targeted therapeutics market during the forecast period. Significant infrastructure for developmental research, availability of substantial research funds, and government initiatives towards RNA-based therapeutics are propelling the market growth. Further, the advancements in RNA technology, particularly mRNA vaccines, as well as the growing application of RNA-based therapies in oncology and rare diseases, are promoting the market growth.
Asia Pacific is anticipated to grow at the fastest pace in the global RNA targeted therapeutics market during the forecast period. Development of innovative medical technologies, along with an increasing prevalence of conditions like cancer, viral infections, and genetic disease, is propelling the RNA targeted therapeutics market. In addition, the upsurging investment in biotechnology and growing healthcare expenditure, along with an increasing focus on precision medicine, are promoting the market.
Europe is anticipated to hold a significant share of the RNA targeted therapeutics market during the projected timeframe. Regional government support, along with the emphasis on personalized medicine and chronic disease prevalence, is contributing to the market growth for RNA targeted therapeutics. The upsurging focus on personalized medicine, along with an increasing research & development activities, is contributing to promoting the market growth.
Major vendors in the global RNA targeted therapeutics market are Abivax, AC Immune, Arrakis Therapeutics, eFFECTOR Therapeutics, Eloxx Pharmaceuticals, H3 Biomedicine, PTC Therapeutics, Ribometrix, Skyhawk Therapeutics, STORM Therapeutics, and Others.
Key Target Audience
- Market Players
- Investors
- End-users
- Government Authorities
- Consulting and Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
Key Market Development
- In April 2024, SiSaf Ltd., an RNA delivery and therapeutics company, announced that SIS-101-ADO, its siRNA therapeutic for patients with autosomal dominant osteopetrosis Type 2 (ADO2), has been granted orphan drug designation by the U.S. FDA.
Market Segment
This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the RNA targeted therapeutics market based on the below-mentioned segments:
Global RNA Targeted Therapeutics Market, By Type of Target Molecule
- Cap Binding Complex
- CDKL5
- Dystrophin Protein
- G542X
- MNK1/MNK2
- PAX6 gene
- SMN2
Global RNA Targeted Therapeutics Market, By Type of Approach
- Indirect RNA Targeting
- mRNA Translation Modulation
- RNA Splicing Modification
Global RNA Targeted Therapeutics Market, By Regional Analysis
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- South Africa
- Rest of the Middle East & Africa
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?